Changes in the MRI Signal in Patients With Benign Tumors of the Brain and Meninges Treated With Proton Therapy: Impact of TEL and the Biological Dose Received

Lead Sponsor

Centre Francois Baclesse

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

•Histologically proven or highly probable grade I meningiomas, histologically proven grade II meningiomas.
•Only meningiomas of the anterior and middle floors of the base of the skull are included.
•Indication of proton therapy retained in RCP and / or proton therapy technical staff (Caen site)
•Patient aged 18 or over
•Patient affiliated to a social security scheme
•Signature of informed consent before any specific procedure related to the study

•History of brain or face irradiation.
•Implant or foreign body that can alter MRI imaging.
•Contraindication to MRI (pace maker, claustrophobia ...) - Hypersensitivity to gadoteric acid, to meglumine or to any medicine containing gadolinium
•Genetic radio sensitizing syndrome
•Known neurological comorbidities (stroke, Parkinson's, etc.) that may impact MRI data.
•Simultaneous participation in a therapeutic clinical trial
•Patient unable to undergo the trial follow-up for geographic, social or psychopathological reasons
•Pregnant or breastfeeding women
•Persons deprived of their liberty (see article L 1121-6 CSP),
•Adults who are the subject of a legal protection measure or unable to express their consent (see article L 1121-8)

Related studies

NCT05055648 · Esophageal Cancer, Radiotherapy, and more

NCT04832620 · Bone Neoplasm of Vertebral Column, Chordoma, and more

NCT02571946 · Liver Neoplasm, Portal Vein Tumor Thrombosis, and more

NCT05914142 · Solid Tumor, Radiation Therapy, and more

NCT02632864 · Liver Neoplasm, Proton Therapy